Ensuring Transfusion Safety for Multiple Myeloma Patients Receiving Anti-CD38 Monoclonal Antibody Therapy
A complimentary CME-certified grand rounds series hosted by RedMedEd and brought to you by the University of Cincinnati, AABB and RedMedEd.
How to Participate
Monoclonal antibody (mAb) therapy is another significant advancement for patients with relapsed multiple myeloma (MM). It was recently observed, however, that MM patients receiving anti-CD38 mAb therapy showed false-positive results in routine blood compatibility tests. This problem (panreactivity) complicates pretransfusion testing and potentially delays the administration of appropriate blood products for transfusion. Strategies for mitigating anti-CD38 mAb interference with blood compatibility testing are available, but institutions may lack protocols for informing transfusion services when a patient is scheduled to begin anti-CD38 mAb therapy—a gap that can lead to delays in issuing RBCs units to patients.
After participating in the educational activity, participants should be able to:
- Describe the mechanism by which anti-CD38 mAbs interfere with blood compatibility testing.
- Evaluate specific methodologies that can overcome the blood compatibility testing interference caused by anti-CD38 mAbs.
- Improve communication between oncologists and blood bankers to minimize the delay in issuing RBC units to patients receiving anti-CD38 mAb therapy.
Personnel involved in transfusion medicine and MM patient management are encouraged to attend. This activity is designed to meet the educational needs of medical directors, laboratory supervisors and administrators, transfusion specialists, cellular therapy and blood banking professionals, medical technologists, hematologists, hematologist-oncologists, medical oncologists, and nurses.
Continuing Education Credits
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and RedMedEd. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
Physicians Credit Designation Statements
The University of Cincinnati designates the live activity for a maximum of 1.0 AMA
PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The University of Cincinnati designates the enduring material for a maximum of 0.75
AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing education credit certificates of attendance/participation for non-physicians are available. Please note: Non-physicians should check with their respective accrediting boards regarding credit reciprocity.
Richard Kaufman, MD—Activity Chair
Associate Professor of Pathology, Harvard Medical School
Medical Director, Adult Transfusion Service, Brigham and Women’s Hospital
Claudia S. Cohn, MD, PhD
Associate Professor, Department of Laboratory Medicine and Pathology
Medical Director, Blood Bank Laboratory
University of Minnesota
Meghan Delaney, DO, MPH
Associate Professor, Department of Laboratory Medicine, University of Washington
Medical Director, Immunohematology and RBC Genomics Reference Laboratory
Mark K. Fung, MD, PhD
Professor of Pathology and Laboratory Medicine
University of Vermont College of Medicine
Connie M. Westhoff, SBB, PhD
Director, Immunohematology and Genomics
New York Blood Center
New York, New York
Adjunct Assistant Professor
University of Pennsylvania